Simplivia Healthcare Ltd. – Trademark Portfolio
Entity Type: 16
Simplivia Healthcare Ltd. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 10 (Medical Apparatus) — 4 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include ARMORE, CHEMFORT, SIMPLIVIA, and TOXI-GUARD. The owner is based in 1101801 Qiryat Shemona.
1 Eli Horvitz Street
North Industrial Zone, P.O.B. 888
1101801 Qiryat Shemona , IL
Showing of trademarks Trademarks
Trademark Classifications
Simplivia Healthcare Ltd.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Simplivia Healthcare Ltd. have?
Simplivia Healthcare Ltd. has 4 U.S. trademarks filed with the USPTO. Of these, 4 registered.
What trademark classes does Simplivia Healthcare Ltd. file in?
Simplivia Healthcare Ltd. files trademarks across 3 Nice Classification classes. The most active classes are Class 10 (Medical Apparatus), Class 44 (Medical Services), Class 5 (Pharmaceuticals). Class 10 covers surgical, medical, dental and veterinary apparatus and instruments.
What are Simplivia Healthcare Ltd.'s most well-known trademarks?
Simplivia Healthcare Ltd.'s registered trademark portfolio includes well-known marks such as ARMORE, CHEMFORT, SIMPLIVIA, and TOXI-GUARD. These are among 4 currently registered trademarks in the portfolio.
What is Simplivia Healthcare Ltd.'s trademark registration success rate?
Simplivia Healthcare Ltd. has a 100% trademark registration rate, with 4 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.